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ABSTRACT
Objective: To investigate the plasma asymmetric dimethylarginine (ADMA) levels and l-arginine in the essential 
hypertension (EH) patients without coronary artery disease. Patients and Methods: A total of 86 Chinese 
patients were enrolled in this study. All patients received coronary multidetector-row computed tomography 
to exclude distinct coronary stenosis and treadmill exercise testing to exclude microvascular angina pectoris. 
The patients with normal blood pressure (n = 26) were set as the control group. The EH patients were divided 
into three subgroups: the prehypertension group (n = 26), the stage 1 hypertension group (n = 26) and the stage 
2 hypertension group (n = 8). The plasma ADMA and l-arginine concentrations were measured by a validated 
high-throughput liquid chromatographic tandem mass spectrometric assay. Results: There was a significantly 
higher ADMA level [0.028 (0.016) mmol/L vs. 0.021 (0.010) mmol/L, P = 0.002] and lower l-arginine to ADMA 
ratio [1.42 (0.58) vs. 2.01 (0.99), P < 0.001] in the EH group compared with the control group. Among the EH 
patients, the ADMA levels were increased by grades of hypertension [0.028 (0.011) mmol/L, 0.027 (0.014) 
mmol/L, 0.035 (0.024) mmol/L, respectively, P < 0.001]. The ADMA level was independently related to the 
systolic blood pressure (r = 1.047, P = 0.001). Conclusion: The plasma ADMA levels were significantly elevated 
with grades of hypertension in EH patients and were positively related to the systolic blood pressure levels.
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(ADMA) is a naturally occurring amino acid and is 
produced by methylation of arginine residues of the 
intracellular proteins.[1] It inhibits the NOS activity, leading 
to the derangement of vasoprotective and vasodilatory 
effect of NO. ADMA contributes to the cardiovascular 
disease pathogenesis related to endothelial dysfunction, 
including atherosclerosis, hyperlipidemia, diabetes mellitus, 
and others.[2] A low ratio of i-arginine to ADMA is a marker 
of endothelial dysfunction and is also associated with all-
cause mortality.[3]
The present study included a highly selected group with 
essential hypertension (EH) without the coronary disease. 
The relationship of the ADMA levels between the EH 
patients and the controls (with normal blood pressure), and 
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INTRODUCTION
Endothelium-derived nitric oxide (NO) is a potent 
vasodilator that plays a critical role in maintaining 
vascular homeostasis through its anti-atherogenic and 
antiproliferative effects on the vascular wall. NO is 
synthesized from its precursor, l-arginine, by endothelial 
NO synthase (NOS). Asymmetric dimethylarginine 178 Journal of Cardiovascular Disease Research Vol. 2 / No 3
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also different ADMA levels among the different stages of 
hypertension were both investigated.
PATIENTS AND METHODS
Patients
A total of 86 Chinese patients were enrolled in this study. 
All patients received the coronary multidetector-row 
computed tomography to exclude the distinct coronary 
stenosis and the treadmill exercise testing to exclude the 
microvascular angina pectoris. None of the patients had 
family history of hypertension. The patients with suspected 
secondary causes of hypertension were eliminated by 
necessary laboratory measurements. The exclusion criteria 
included ischemic heart disease, congestive heart failure, 
atrial fibrillation, chronic renal insufficiency, and a history 
of stroke. Ischemic heart disease was defined as being 
present in patients with >50% stenosis of a major coronary 
artery on coronary angiography or a history of myocardial 
infarction or percutaneous coronary intervention. Heart 
failure was defined as a history of dyspnea or exercise 
intolerance associated with signs of pulmonary congestion 
or peripheral edema. Cardiac enlargement or dysfunction 
shown by chest radiography or echocardiography was 
also a diagnostic criterion. The study was approved by the 
institutional review board of the First Affiliated Hospital 
of Bengbu Medical College.
Definition of hypertension
Blood pressures of the patients were measured at the brachial 
artery with an automatic pressure gauge after a resting 
period of at least 5 min. The same physician performed all 
measurements. The mean of the measurements on two sides 
of brachial artery was used as the systolic blood pressure 
(SBP) and diastolic blood pressure (DBP). Hypertension 
was defined as SBP >140 mmHg and/or DBP >90 mmHg 
on the repeated measurements with or without any oral 
anti-hypertension drug. The patients with normal blood 
pressure (n = 26) were set as the control group. According 
to current hypertension guideline,[4] the EH patients were 
divided into three subgroups: the prehypertension group   
(n = 26), the stage 1 hypertension group (n = 26) and the 
stage 2 hypertension group (n = 8).
Assays for ADMA, l-arginine, and other biomarkers
Laboratory assessment of several biomarkers was 
conducted on samples drawn in the morning after at least 
12 h of fasting. Plasma samples were stored at −80°C and 
used for mass spectrometric determination of ADMA 
and l-arginine using a validated high-throughput liquid 
chromatographic tandem mass spectrometric assay.[5] All 
plasma samples were measured by the same assay. Glucose, 
uric acid, total cholesterol, triglyceride, and high-density 
lipoprotein cholesterol levels were measured by the 
enzymatic colorimetric method with an Olympus AU600 
auto-analyzer using reagents from Olympus Diagnostics.
Statistical analysis
The variables with normal distribution were reported 
as mean ± standard deviation and were compared using 
Student’s t-test. The variables with non-normal distribution 
were reported as median (quartile range) and were compared 
by Wilcoxon’s test. Discrete variables were compared by 
chi-square or Fisher’s exact test. ADMA-related analysis 
used multivariate logistic regression analysis. A value of 
P < 0.05 was considered statistically significant. Statistical 
analysis was performed with SAS software (Version 9.1, 
SAS Institute Inc., Cary, NC, USA).
RESULTS
Clinical characteristics
Table 1 shows the clinical characteristics in the EH group 
and the control group. There were no statistical differences 
between the EH group and the control group in terms of 
sex, age, glucose, uric acid, triglycerides, total cholesterol 
and high-density lipoprotein cholesterol.
Plasma ADMA and l-arginine concentrations
There was a significantly higher ADMA level [0.028 
(0.016) mmol/L vs. 0.022 (0.010) mmol/L, P = 0.002] 
and lower l-arginine to ADMA ratio [1.42 (0.58) vs. 
2.01 (0.99), P < 0.001] in the EH group compared to the 
control group. Among the patients, the ADMA levels 
were increased by grades of hypertension [0.028 (0.011) 
mmol/L, 0.027 (0.014) mmol/L, 0.035 (0.024) mmol/L, 
respectively, P < 0.001). There was no significant difference 
in the l-arginine levels among the patients [Table 1 and 
Figure 1]. The ADMA concentrations were found to 
be independently related to the SBP levels (r = 1.047,   
P = 0.001) after multivariate logistic regression analysis.
DISCUSSION
The results of this study, which was performed in EH 
patients without coronary disease, showed that the plasma 
ADMA levels were significantly elevated in EH patients 
and were positively related to the SBP levels.179 Journal of Cardiovascular Disease Research Vol. 2 / No 3
Wang, et al.: Asymmetric dimethylarginine and essential hypertension
Endothelium-derived NO is the most potent endogenous 
substance exerting its beneficial effects by stimulation 
of soluble guanylate cyclase to produce cyclic GMP.[6] 
It is synthesized by the endothelial enzyme NOS from 
l-arginine. A large amount of data indicates that ADMA 
may be responsible for endothelial dysfunction in subjects 
with vascular diseases and in those with cardiovascular risk 
factors in whom ADMA plasma levels have been found 
to be elevated.[7]
The ADMA has been identified as an independent 
predictor of morbidity and mortality in patients with 
different cardiovascular diseases.[3] Elevated ADMA 
levels have been documented in different clinical 
conditions such as dyslipidemia, high BP, diabetes and 
acute coronary syndrome, all associated with endothelial 
dysfunction.[8] We found in our previous study that the 
plasma ADMA concentrations are increased in acute 
coronary syndrome.[9] We also found that the ADMA 
levels are positively correlated to the degree of coronary 
atherosclerosis.[10]
NO plays an important role in the regulation of vascular 
tonus and blood pressure. NOS inhibition has been shown 
to cause a decrease in renal sodium excretion, which 
may also contribute to hypertension. ADMA has potent 
vasoconstrictor/pressor effects by inhibiting NOS. Further, 
exogenously administered ADMA was reported to decrease 
renal sodium excretion in healthy human subjects.[11] Thus, 
we hypothesized that ADMA may be involved in the 
pathogenesis of hypertension. Our data indicated that 
ADMA levels were higher in a high selected EH patients 
than that in the control group after excluded from coronary 
artery disease. In a recent study, ADMA levels were found 
to be significantly higher in 30 younger males with EH.[12] 
However, that study did not exclude coronary atherosclerotic 
heart disease which is an important influencing factor of 
ADMA testified by our previous research.[10]
l-arginine is the substrate for the endothelial NOS 
synthase to generate NO. The plasma l-arginine level varies 
according to the daily diet. The l-arginine to ADMA ratio 
has been used to represent the NO bioavailability.[13] A 
Table 1: The patients’ clinical characteristics
EH group (n = 34) Control group (n = 52) X/t value P value
Sex (male/%) 20/58.2 24/46.5 1.32 0.251
Age (years) 58.9±12.5 53.5±16.1 2.06 0.056
Blood glucose (mmol/L) 4.8±0.6 4.8±0.5 −0.27 0.787
Uric acid (mmol/L) 354.9±115.2 340.8±139.2 −0.49 0.626
Triglycerides (mmol/L) 1.99±0.79 1.80±1.03 −0.91 0.366
Total cholesterol (mmol/L) 4.87±1.05 4.63±0.95 −1.12 0.265
High-density lipoprotein (mmol/L) 1.29±0.28 1.25±0.33 −0.70 0.483
SBP (mmHg) 140 (20) 120 (10) 62.28 <0.001
DBP (mmHg) 100 (20) 80 (5) 59.91 <0.001
Heart rate (bpm) 75±8 70±10 8.09 0.054
ADMA (mmol/L) 0.028 (0.016) 0.021 (0.010) 14.44 0.002
l-arginine (mmol/L) 0.045±0.008 0.047± 0.009 0.99 0.323
l-arginine to ADMA ratio 1.42 (0.58) 2.01 (0.99) 16.95 <0.001
Figure 1: The ADMA, l-arginine levels (left) and the l-arginine to ADMA ratio (right) in EH patients with different stages of hypertension and 
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lower l-arginine to ADMA ratio is associated with high risk 
of death and cardiovascular disease events in the general 
population.[8] In a large community-based sample, the ratio 
of l-arginine to ADMA is significantly associated with the 
all-cause mortality.[3] Our previous study also indicated that 
the ratio of l-arginine to ADMA decreased in patients with 
acute coronary syndrome.[9] Reduced l-arginine to ADMA 
ratio is found to correlate with a decreased endothelial-
dependent flow-mediated vasodilatation in patients with 
hypercholesterolemia,[14] hyperhomocysteinemia[15] and 
hypertriglyceridemia.[16] In this study, we found that a lower 
l-arginine to ADMA ratio existed in EH patients without 
coronary artery disease. Inhibition of NOS activity may be 
overcome by increased extracellular l-arginine to ADMA 
ratio through excess substrate. So, supplementation with 
l-arginine may be able to restore the physiological status 
by normalizing the extracellular l-arginine to ADMA ratio. 
This implicates further therapeutic options for l-arginine 
supplementation for EH patients.
Limitations
There were several limitations of the present study. Many 
of the EH patients in our study received anti-hypertension 
drugs such as the vasodilatation drugs, which can influence 
the results. Furthermore, we did not assess the diastolic 
function of left ventricle, and it is conceivable that 
plasma ADMA is associated with left ventricular diastolic 
dysfunction. Blood pressure is also responsive to many 
factors such as alcohol assumption, smoking, diet and 
exercise, body mass index, air pollution, etc. which we did 
not analyze in this study.
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